Novartis to acquire kidney disease drug maker Regulus Therapeutics for up to 1.7 billion Ruchika Sharma1 May 2025 12:30 PM ISTTransaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a future regulatory...
Novartis plans to invest USD 23 billion over next 5 years in US based infrastructure Ruchika Sharma13 April 2025 12:30 PM ISTEast Hanover: Novartis, a global medicines company, has announced a planned USD 23 billion investment over 5 years in US-based infrastructure,...
FDA Grants Accelerated Approval to Atrasentan for IgA Nephropathy Dr. Kamal Kant Kohli5 April 2025 9:30 AM ISTThe US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary immunoglobulin A (IgA)...
Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy Ruchika Sharma3 April 2025 4:30 PM ISTEast Hanover: Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia...
Novartis appoints Karen Hale as Chief Legal and Compliance Officer Ruchika Sharma31 March 2025 2:55 PM ISTBasel: Novartis has announced the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for Novartis, effective...
Novartis radioligand therapy Pluvicto gets USFDA nod for expanded indication Ruchika Sharma29 March 2025 1:15 PM ISTBasel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for...
Novartis oral Fabhalta secures USFDA okay for adults with C3 glomerulopathy Ruchika Sharma21 March 2025 12:42 PM ISTBasel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the treatment...
CDSCO Panel Approves Updated Package Insert for Novartis' Ofatumumab Injection Dr. Divya Colin16 March 2025 5:45 PM ISTNew Delhi:The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the proposal...
Novartis Gets CDSCO Panel Nod To Study Antiparasitic drug LXE408 Dr. Divya Colin7 March 2025 5:15 PM ISTNew Delhi: Drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Novartis oral Fabhalta receives positive EMA Committee opinion for adults with C3 glomerulopathy Ruchika Sharma3 March 2025 10:30 AM ISTBasel: Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...
Sandoz family foundation offers USD 3 billion worth of Novartis shares Ruchika Sharma27 Feb 2025 5:04 PM ISTEmasan AG, a subsidiary of the Sandoz Family Foundation, has initiated a public offering of approximately 26.5 million shares in Novartis, aiming to...
Novartis to acquire Anthos Therapeutics for USD 925 million upfront, bolsters late-stage cardiovascular pipeline Ruchika Sharma11 Feb 2025 5:50 PM ISTBasel: Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held,...
